$AQXP (Aquinox Pharmaceuticals Inc.)

$AQXP {{ '2015-08-13T12:19:11+0000' | timeago}} • SEC

$AQXP Form 4: On Aug. 10, 2015, Pfizer Inc. disposed of 259,927 of AQXP’s shares in multiple transactions at prices ranging from a low of $20 to a high of $41.46. Pfizer now owns 975,403 of AQXP’s shares.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

$BAX {{ '2017-07-26T12:42:25+0000' | timeago}} • Announcement

$BAX reported a 78% dip in 2Q17 earnings due to last year's net realized gains from exchange of its retained shares of Baxalta and contribution to its U.S. pension fund. Net income dropped to $265MM or $0.48 per share from $1.21Bil or $2.19 per share last year. Net sales rose 1% to $2.61Bil. Adjusted EPS grew 37% to $0.63.

$VRTX {{ '2017-07-25T21:51:58+0000' | timeago}} • Announcement

$VRTX and $CNCE completed an asset purchase agreement, under which $VRTX gained worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. $CNCE received $160MM in cash upon closing and is eligible to receive up to $90MM in additional milestones.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

Drugmaker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $20.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$LLY {{ '2017-07-25T14:13:17+0000' | timeago}} • Announcement

$LLY, which joined hands with $NKTR recently to co-develop the autoimmune drug NKTR-358, cut down its GAAP earnings outlook for FY17 by $0.09 per share to $2.51-2.61. However, Eli Lilly lifted its non-GAAP EPS estimate to $4.10-4.20 from the prior outlook of $4.05-4.15 Revenue outlook also lifted to $22.0-22.5Bil from prior range of $21.8-22.3Bil.

$LLY {{ '2017-07-25T13:14:16+0000' | timeago}} • Announcement

Drugmaker $LLY reported a jump in its profit for the second quarter 2017, boosted by new pharma products sales and higher realized prices. Profit climbed 35% to $1.01Bil and GAAP EPS surged 34% to $0.91 versus a year ago. Revenue grew 8% to $5.82Bil and non-GAAP EPS spiked up 29% to $1.11.

$LLY {{ '2017-07-25T12:32:52+0000' | timeago}} • Infographic

$LLY Eli Lilly and Company Earnings AlphaGraphic: Q2 2017 Highlights

Recent Transcripts

LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
OMER (Omeros Corporation)
Wednesday, May 10 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
DPLO (Diplomat Pharmacy, Inc.)
Monday, May 8 2017 - 9:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
BAX (Baxter International Inc.)
Wednesday, April 26 2017 - 12:30pm
LLY (Eli Lilly and Company)
Tuesday, April 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
VRML (Vermillion, Inc.)
Wednesday, March 29 2017 - 8:30pm
OMER (Omeros Corporation)
Thursday, March 16 2017 - 8:30pm

AlphaGraphics you may like